| LP265245-3 | Chair alarm used during assessment period | COMPONENT | 1 |
| LP265247-9 | Floor mat alarm used during assessment period | COMPONENT | 1 |
| LP265248-7 | Motion sensor alarm used during assessment period | COMPONENT | 1 |
| LP265249-5 | Wander/elopement alarm used during assessment period | COMPONENT | 1 |
| LP265250-3 | Other alarm used during assessment period | COMPONENT | 1 |
| LP265252-9 | MDS v3.0 - RAI v1.15.1 - Nursing home and Swing bed OMRA (NO and SO) item set | COMPONENT | 1 |
| LP265253-7 | MDS v3.0 - RAI v1.15.1 - Nursing home and Swing bed OMRA start of therapy (NS and SS) item set | COMPONENT | 1 |
| LP265254-5 | MDS v3.0 - RAI v1.15.1 - Nursing home and Swing bed tracking (NT and ST) item set | COMPONENT | 1 |
| LP265255-2 | MDS v3.0 - RAI v1.15.1 - Nursing home comprehensive (NC) item set | COMPONENT | 1 |
| LP265256-0 | MDS v3.0 - RAI v1.15.1 - Nursing home discharge (ND) and Swing bed discharge (SD) item set | COMPONENT | 1 |
| LP265258-6 | MDS v3.0 - RAI v1.15.1 - Nursing home OMRA start of therapy and discharge (NSD) and Swing bed OMRA start of therapy and discharge (SSD) item set | COMPONENT | 1 |
| LP265265-1 | MDS v3.0 - RAI v1.15.1 - Nursing home OMRA-discharge (NOD) and Swing bed OMRA-discharge (SOD) item set | COMPONENT | 1 |
| LP265266-9 | MDS v3.0 - RAI v1.15.1 - Nursing home part A PPS discharge (NPE) item set | COMPONENT | 1 |
| LP265267-7 | MDS v3.0 - RAI v1.15.1 - Nursing home PPS (NP) item set | COMPONENT | 1 |
| LP265268-5 | MDS v3.0 - RAI v1.15.1 - Swing bed PPS (SP) item set | COMPONENT | 1 |
| LP265270-1 | MDS v3.0 - RAI v1.15.1 - Medications | COMPONENT | 1 |
| LP265271-9 | MDS v3.0 - RAI v1.15.1 - Medications - NOD, NP, SOD, SP | COMPONENT | 1 |
| LP265272-7 | MDS v3.0 - RAI v1.15.1 - Medications - NSD, ND, SSD, SD | COMPONENT | 1 |
| LP265274-3 | MDS v3.0 - RAI v1.15.1 - Nursing home quarterly (NQ) item set | COMPONENT | 1 |
| LP265275-0 | Ocular pathogens panel | COMPONENT | 1 |
| LP265276-8 | Natural killer cell cytotoxicity.30:1 effector to target cell ratio | COMPONENT | |
| LP265277-6 | Natural killer cell cytotoxicity.0.9:1 effector to target cell ratio | COMPONENT | |
| LP265278-4 | Natural killer cell cytotoxicity.15:1 effector to target cell ratio | COMPONENT | |
| LP265279-2 | Natural killer cell cytotoxicity.7.5:1 effector to target cell ratio | COMPONENT | |
| LP265280-0 | Natural killer cell cytotoxicity.1.88:1 effector to target cell ratio | COMPONENT | |
| LP265281-8 | Natural killer cell cytotoxicity.3.75:1 effector to target cell ratio | COMPONENT | |
| LP265282-6 | Known exposure | COMPONENT | 1 |
| LP265286-7 | Date specimen was sent to public health laboratory | COMPONENT | 1 |
| LP265289-1 | Helicobacter pylori 23S rRNA clarithromycin resistance mutation | COMPONENT | 1 |
| LP265299-0 | Carbapenem resistance gene identified | COMPONENT | 1 |
| LP265312-1 | How supplied + storage + handling section | COMPONENT | 1 |
| LP265314-7 | Norquetiapine | COMPONENT | 3 |
| LP265315-4 | Clinical significance of updated information | COMPONENT | 1 |
| LP265316-2 | KIT gene c.2447A>T | COMPONENT | 1 |
| LP265326-1 | Computed tomography perfusion and Computerized tomography angio | METHOD | 2 |
| LP265327-9 | Brain and Head vessels | SYSTEM | 2 |
| LP265328-7 | Coronary arteries and Pulmonary veins | SYSTEM | 1 |
| LP265329-5 | Abdomen and Pelvis and Lower extremity - bilateral | SYSTEM | 1 |
| LP265330-3 | Chest and Pulmonary arteries | SYSTEM | 1 |
| LP265331-1 | Neck and Head and neck vessels | SYSTEM | 1 |
| LP265332-9 | Head and Head and neck vessels | SYSTEM | 1 |
| LP265333-7 | Brain and Head and neck vessels | SYSTEM | 1 |
| LP265334-5 | Tildipirosin | COMPONENT | 3 |
| LP265335-2 | Gamithromycin | COMPONENT | 3 |
| LP265578-7 | 50M post dose fructose PO | CHALLENGE | |
| LP265579-5 | 40M post dose fructose PO | CHALLENGE | |
| LP265580-3 | 20M post dose fructose PO | CHALLENGE | |
| LP265581-1 | 10M post dose fructose PO | CHALLENGE | |
| LP265582-9 | 10M post dose lactose PO | CHALLENGE | |
| LP265585-2 | 50M post dose lactose PO | CHALLENGE | |